A number of companies this year have invested and furthered their stake in the photon-counting CT market. Siemens, back in October ,scored FDA clearance for its own system, the NAEOTOM Alpha. The solution is designed to use photon-counting to produce detailed 3D images that can be used to train physicians in diagnosing patients and by staff to make diagnoses, prepare treatment, and in radiation therapy planning.

Prior to this, Canon teamed up in September with the National Cancer Center Japan and EAST Hospital in Kashiwa to further research on the use of photon-counting CT (PCCT). The two are studying the use of its quantitative capabilities of photon counting CT for assessing treatment effects from chemotherapeutic agents on malignant tumors and analyzing different tissue characteristics for clinical insights on a wide range of medical fields.


And just last month, the first silicon-based photon-counting CT system, designed by GE Healthcare, was entered into a clinical pilot study overseen by Karolinska Institutet and MedTechLabs. The main objective is to study the performance of the machine’s Deep Silicon detector technology, which combined with photon-counting CT has the potential to produce stronger spatial resolution. It will also compare the performance to standard CT technology and collect insights for optimizing image processing.

The findings were published in Radiology.

Back to HCB News

CT Homepage